Berenberg keeps EUR 3.60 target for Evotec stock

Published on 10/26/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec reports full results on November 5, 2026. Evotec stock costs EUR 2.82 on October 26, 2026, up 0.36 percent versus the Xetra close.

Analyst target and November date

On October 16, 2026, Berenberg retained its EUR 3.60 target for Evotec.
Evotec will publish full third-quarter and nine-month results on November 5, 2026.
Evotec stock costs EUR 2.82 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CEST, 0.36 percent above the Xetra close of October 23, 2026 at EUR 2.81, and 61.37 percent below the 52-week high.
Evotec's market capitalization is EUR 499.4 million as of October 26, 2026.

Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec SE (ISIN DE0005664809) is facing a measured analyst view after Berenberg retained its EUR 3.60 target and Neutral rating, as MarketScreener reported on October 16, 2026. The target lies 27.66 percent above the EUR 2.82 Lang & Schwarz price. Evotec stock was trading at EUR 2.82 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CEST, 0.36 percent above the Xetra close of October 23, 2026 at EUR 2.81.

Berenberg keeps a neutral stance

Berenberg's target is materially above the current euro quotation, but its rating remains Neutral. The same report said the analyst considered Evotec's preliminary third-quarter figures surprisingly strong while retaining the EUR 3.60 target. That combination leaves the target distance as a valuation reference rather than a change in recommendation.

Stock remains below its yearly high

At EUR 2.82, Evotec is 61.37 percent below its 52-week high of EUR 7.30 and 17.01 percent above its 52-week low of EUR 2.41, both as of October 26, 2026. The company's market capitalization was EUR 499.4 million on that date, while its year-to-date performance stood at minus 47.63 percent. The price therefore remains close to the lower end of its annual range despite the recent analyst coverage.

What comes on November 5?

The next scheduled financial checkpoint is November 5, 2026, when Evotec plans to publish full third-quarter and first-nine-month results, according to the company's preliminary release carried by MarketScreener on October 13, 2026. Preliminary revenue for the first nine months of 2026 was EUR 465.0 million, while adjusted EBITDA was a loss of EUR 42.8 million. Both figures were above market expectations, but Evotec reaffirmed full-year 2026 revenue guidance of EUR 570.0 million to EUR 610.0 million and adjusted EBITDA guidance of a loss of EUR 70.0 million to EUR 105.0 million.

Price and next checkpoint

The November report will test whether the better preliminary revenue figure can translate into more dependable operating results. For now, the numerical contrast is clear: nine-month revenue reached EUR 465.0 million, while the full-year adjusted EBITDA outlook remains negative. Berenberg's EUR 3.60 target is 27.66 percent above the current EUR 2.82 price.

Evotec stock was trading at EUR 2.82 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CEST, 0.36 percent above the Xetra close of October 23, 2026 at EUR 2.81. The stock stood 61.37 percent below its 52-week high of EUR 7.30. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.